STARLIX
LOE ApproachingNDAORALTABLET
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STARLIX is an oral small-molecule tablet approved by the FDA in December 2000 under NDA. The specific indication and mechanism of action are not detailed in available data, but the product is positioned as a Novartis oral therapeutic. It is classified as a small-molecule modality with a standard tablet dosage form.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30 rating), indicating a brand team in transition planning mode with likely downsizing or pivot opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STARLIX currently has zero linked job openings, indicating minimal hiring momentum and a mature, stable team structure. Working on STARLIX offers exposure to lifecycle management and generic transition strategies, valuable for early-career pharma professionals learning how to defend market position during LOE.
Brand ManagerField Sales Representative
Worked on STARLIX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.